Shares of Illumina Inc. (NASDAQ:ILMN) have been given a consensus rating of “Hold” by the twenty-seven research firms that are currently covering the firm. Four research analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $149.48.

ILMN has been the subject of several research analyst reports. Vetr upgraded Illumina from a “sell” rating to a “buy” rating and set a $198.61 price target for the company in a report on Monday, October 3rd. Citigroup Inc. raised their price target on Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a report on Monday, September 12th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target for the company in a report on Friday, August 26th. Argus raised their price target on Illumina from $175.00 to $185.00 and gave the company a “buy” rating in a report on Monday, August 8th. Finally, Barclays PLC set a $142.00 price target on Illumina and gave the company an “equal weight” rating in a report on Tuesday, October 11th.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $171.25, for a total transaction of $102,750.00. Following the sale, the director now owns 17,065 shares in the company, valued at approximately $2,922,381.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 300 shares of the business’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $174.29, for a total value of $52,287.00. Following the sale, the director now owns 6,924 shares in the company, valued at approximately $1,206,783.96. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ILMN. Physicians Financial Services Inc. increased its stake in shares of Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the last quarter. Global X Management Co. LLC increased its stake in shares of Illumina by 1,400.0% in the third quarter. Global X Management Co. LLC now owns 600 shares of the life sciences company’s stock worth $109,000 after buying an additional 560 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Illumina during the second quarter worth approximately $112,000. Finally, Ropes Wealth Advisors LLC increased its stake in shares of Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares during the last quarter. Institutional investors and hedge funds own 93.52% of the company’s stock.

Shares of Illumina (NASDAQ:ILMN) traded down 0.93% during trading on Wednesday, hitting $133.50. The company had a trading volume of 364,021 shares. The company has a market capitalization of $19.61 billion, a P/E ratio of 44.80 and a beta of 1.24. Illumina has a 52 week low of $127.10 and a 52 week high of $196.47. The stock’s 50-day moving average price is $144.41 and its 200 day moving average price is $152.98.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.10. The company had revenue of $607 million for the quarter, compared to the consensus estimate of $628.06 million. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the company earned $0.80 EPS. On average, equities research analysts forecast that Illumina will post $3.32 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Illumina Inc. (ILMN) Receives Average Recommendation of “Hold” from Analysts” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/23/illumina-inc-ilmn-receives-average-recommendation-of-hold-from-analysts.html.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.